Benign prostatic hyperplasia and prostate cancer differentiation via platelet to lymphocyte ratio

Basit Öğe Kaydı
dc.authoridRoses, Murat/0000-0003-0215-6343|Goktas, Serdar/0000-0001-6538-7187|Kaynar, Mehmet/0000-0002-6957-9060|Gul, Murat/0000-0002-6657-6227|YILDIRIM, MEHMET/0000-0003-4768-4537
dc.contributor.authorKaynar, Mehmet
dc.contributor.authorYildirim, Mehmet Erol
dc.contributor.authorGul, Murat
dc.contributor.authorKilic, Ozcan
dc.contributor.authorCeylan, Kadir
dc.contributor.authorGoktas, Serdar
dc.date.accessioned2025-10-24T18:09:46Z
dc.date.available2025-10-24T18:09:46Z
dc.date.issued2015
dc.departmentMalatya Turgut Özal Üniversitesi
dc.description.abstractBACKGROUND: The aim of the current study is to evaluate NLR and PLR inflammation markers in PCa and BPH. METHODS: Clinical and pathological data such as age, prostate volume, PSA, NLR, and PLR levels of 201 patients were retrospectively reviewed. Pathological sample results of these patients were categorized either as benign or malign. The benign group consisted of chronic prostatitis and BPH and the malign group of PCa. The PSA levels were divided into three categories as PSA: 0-4 ng/ml, PSA: 4-10 ng/ml, and 10 ng/ml and above. RESULTS: In the benign category, the mean PLR values for PSA: 0-4 ng/ml is 131.8 +/- 31.2, for PSA: 4-10 ng/ml 124.7 +/- 83.9 and 10 ng/ml and above 124 +/- 53 in chronic prostatitis group and in the BPH group for PSA: 4-10 ng/ml 120.3 +/- 45.1, for PSA: 4-10 ng/ml 126 +/- 54,2, and 10 ng/ml and above 191.4 +/- 176.1. In the malign category, the mean PLR values of PCa patients is for PSA: 0-4 ng/ml 122.8 +/- 43.8, for PSA: 4-10 ng/ml 123 +/- 43.8, and above 10 ng/ml 179.1 +/- 94. Related to the variables of age, NLR, and mean prostate volume, there were no statistically significant differences. Statistically significant differences were observed in the mean PLR values only if the PSA level was 10 ng/ml and above (p: 0.044) in the BPH and PCa groups. The correlation of the PCa Gleason score and PSA, NLR and PLR parameters in the malign category revealed no statistically significant differences (P > 0.05). CONCLUSION: Effective malign and benign differentiation of prostate pathologies based on noninvasive inflammation biomarkers such NLR and PLR necessitate clinical studies with larger patient series.
dc.identifier.doi10.3233/CBM-150458
dc.identifier.endpage323
dc.identifier.issn1574-0153
dc.identifier.issn1875-8592
dc.identifier.issue3
dc.identifier.pmid25586096
dc.identifier.scopus2-s2.0-84931045121
dc.identifier.scopusqualityQ2
dc.identifier.startpage317
dc.identifier.urihttps://doi.org/10.3233/CBM-150458
dc.identifier.urihttps://hdl.handle.net/20.500.12899/3815
dc.identifier.volume15
dc.identifier.wosWOS:000355954400012
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherIos Press
dc.relation.ispartofCancer Biomarkers
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_20251023
dc.subjectBenign prostatic hyperplasia; prostate cancer; platelet to lymphocyte ratio
dc.titleBenign prostatic hyperplasia and prostate cancer differentiation via platelet to lymphocyte ratio
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu